Raptiva

Raptiva, also known by its generic name efalizumab, is a monoclonal antibody used to treat plaque psoriasis. It is administered through subcutaneous injection and works by blocking the interaction between certain immune cells and the skin, thereby reducing inflammation and scaling. Raptiva is typically prescribed for moderate to severe plaque psoriasis that has not responded to other treatments. Common side effects include injection site reactions, headache, and upper respiratory tract infections. Serious side effects may include an increased risk of infections and allergic reactions. Raptiva is available in various strengths and formulations to suit different patient needs. It is important for patients to follow their healthcare provider's instructions for dosage and administration to maximize its effectiveness and minimize side effects.